Our Mission

Cascure Therapeutics: building a new future for cancer treatment technology.
Cascure Therapeutics develops highly selective anticancer medicines using the CINDELA (Cancer-specific INDELA Attacker) platform, which targets mutation sequences found only in tumor cells. Our mission is to deliver a first-in-class CRISPR-based therapy and give patients a life free from the fear of cancer.

Today, for about KRW 1 million (approximately USD 1,000), clinicians can easily pinpoint the genetic defects in a patient’s cancer cells. Yet, despite many personalized therapies that use this information, cancer remains a formidable disease that endangers patients and their families. Metastasis and recurrence, in particular, cause a large share of cancer-related deaths and continue to instill fear.

Cascure has combined tumor-genome insights with CRISPR gene editing to create the CINDELA platform. CINDELA continues to work without resistance even in cases of recurrence and metastasis. This new therapy has fewer side effects and can be offered to patients at a lower cost than traditional cancer treatments.

 

 

 

Leadership

  •  

    Operation
    Jongmoon Kim
    CEO, CasCure
    3Over 30 years of Experience in IT/BT operations
  • Target Identification

    Bioinformatics
    Taejoon Kwon Ph.D.
    CTO, CasCure
    Prof. of UNIST
    (Biomedical Engineering)
  • CRISPR/Cas Design

    CRISPR/Cas
    Seungwoo Cho Ph.D.
     
    Prof. of UNIST
    (Biomedical Engineering)
  • Boosting with drugs

    DNA repair
    Kyungjae Myung Ph.D.
     
    Director of Institute
    of Basic Science Distinguished prof. of UNIST
  • In vivo Delivery

    Delivery
    Jinmyoung Joo Ph.D.
     
    Prof. of UNIST
    (Biomedical Engineering)

 

 

Overview

Company Cascure Therapeutics
Founding 2020.06.30
CEO Jongmoon Kim
Head Office UNIST, Ulsan, Korea
R&D center Magok, Seoul, Korea
Shareholders
(Jan. 2025)
Founder and management (60.94%) / Individuals (3.92%)
3 Investments (25.53%) / 2 Researches institute (3.84%)
Private Investment Funds (5.77%)